Compare Roivant Sciences Ltd. Common Shares (ROIV) vs Solstice Advanced Materials Inc. Common Stock (SOLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roivant Sciences Ltd. Common Shares vs Solstice Advanced Materials Inc. Common Stock — how do they compare? Roivant Sciences Ltd. Common Shares trades at $33.68 (market cap $24.99B), while Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.68B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.6× Solstice Advanced Materials Inc. Common Stock's market cap, and Solstice Advanced Materials Inc. Common Stock pays a 0.49% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 3 Days and Solstice Advanced Materials Inc. Common Stock for 0 Days on average.
| ROIV | SOLS | |
|---|---|---|
Market Cap | $24.99B | $9.68B |
Volume | 4,711,562 | 1,519,067 |
Sector | Health | Basic Materials |
52-Week High | $41.81 | $88.60 |
52-Week Low | $16.99 | $41.43 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $21.25B | $11.35B |
Dividend Yield | — | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →About Solstice Advanced Materials Inc. Common Stock
Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →
